December, 05th | 14:03 - 14:06
Talon, a phase iiib study of brolucizumab versus aflibercept in a matched (treat-and-extend) regimen in patients with neovascular age-related macular degeneration: 64-week results
VADALÀ MARIA
Full program
Add to calendar